384 related articles for article (PubMed ID: 36034814)
1. Licensing of Orphan Medicinal Products-Use of Real-World Data and Other External Data on Efficacy Aspects in Marketing Authorization Applications Concluded at the European Medicines Agency Between 2019 and 2021.
Naumann-Winter F; Wolter F; Hermes U; Malikova E; Lilienthal N; Meier T; Kalland ME; Magrelli A
Front Pharmacol; 2022; 13():920336. PubMed ID: 36034814
[No Abstract] [Full Text] [Related]
2. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
[TBL] [Abstract][Full Text] [Related]
3. Advancing rare disease treatment: EMA's decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation.
Kalland ME; Pose-Boirazian T; Palomo GM; Naumann-Winter F; Costa E; Matusevicius D; Duarte DM; Malikova E; Vitezic D; Larsson K; Magrelli A; Stoyanova-Beninska V; Mariz S
Gene Ther; 2024 Mar; ():. PubMed ID: 38480914
[TBL] [Abstract][Full Text] [Related]
4. Regulatory Aspects for Approval of Advanced Therapy Medicinal Products in the EU.
Fürst-Ladani S; Bührer A; Fürst W; Schober-Ladani N
Handb Exp Pharmacol; 2024; 284():367-387. PubMed ID: 37017789
[TBL] [Abstract][Full Text] [Related]
5. Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs.
Giannuzzi V; Landi A; Bosone E; Giannuzzi F; Nicotri S; Torrent-Farnell J; Bonifazi F; Felisi M; Bonifazi D; Ceci A
BMJ Open; 2017 Sep; 7(9):e017358. PubMed ID: 28893754
[TBL] [Abstract][Full Text] [Related]
6. Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit.
Mulder J; Teerenstra S; van Hennik PB; Pasmooij AMG; Stoyanova-Beninska V; Voest EE; de Boer A
ESMO Open; 2023 Apr; 8(2):101209. PubMed ID: 37054504
[TBL] [Abstract][Full Text] [Related]
7. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
Iglesias-Lopez C; Obach M; Vallano A; Agustí A
Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
[TBL] [Abstract][Full Text] [Related]
8. Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012.
Pauwels K; Huys I; Casteels M; Larsson K; Voltz C; Penttila K; Morel T; Simoens S
Orphanet J Rare Dis; 2017 Feb; 12(1):36. PubMed ID: 28209180
[TBL] [Abstract][Full Text] [Related]
9. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.
Joppi R; Bertele' V; Garattini S
Eur J Clin Pharmacol; 2013 Apr; 69(4):1009-24. PubMed ID: 23090701
[TBL] [Abstract][Full Text] [Related]
10. Comparison between European Medicines Agency and US Food and Drug Administration in Granting Accelerated Marketing Authorizations for Covid-19 Medicines and their Utilized Regulations.
Ghadanian M; Schafheutle E
Ther Innov Regul Sci; 2024 Jan; 58(1):79-113. PubMed ID: 37861859
[TBL] [Abstract][Full Text] [Related]
11. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
12. Traits, trends and hits of orphan drug designations in cystic fibrosis.
Costa E; Girotti S; van den Ham HA; Cipolli M; van der Ent CK; Taylor-Cousar JL; Leufkens HGM
J Cyst Fibros; 2023 Sep; 22(5):949-957. PubMed ID: 37507282
[TBL] [Abstract][Full Text] [Related]
13. Trends in orphan medicinal products approvals in the European Union between 2010-2022.
Bouwman L; Sepodes B; Leufkens H; Torre C
Orphanet J Rare Dis; 2024 Feb; 19(1):91. PubMed ID: 38413985
[TBL] [Abstract][Full Text] [Related]
14. Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network.
Heard JM; Vrinten C; Schlander M; Bellettato CM; van Lingen C; Scarpa M;
Orphanet J Rare Dis; 2020 Jan; 15(1):3. PubMed ID: 31907071
[TBL] [Abstract][Full Text] [Related]
15. From promising molecules to orphan drugs: Early clinical drug development.
Dooms M
Intractable Rare Dis Res; 2017 Feb; 6(1):29-34. PubMed ID: 28357178
[TBL] [Abstract][Full Text] [Related]
16. Access to medicines for rare diseases: A European regulatory roadmap for academia.
Rosenberg N; van den Berg S; Stolwijk NN; Jacobs BAW; Post HC; Pasmooij AMG; de Visser SJ; Hollak CEM
Front Pharmacol; 2023; 14():1142351. PubMed ID: 36925633
[No Abstract] [Full Text] [Related]
17. Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe.
Jonker CJ; Bakker E; Kurz X; Plueschke K
Front Pharmacol; 2022; 13():924648. PubMed ID: 35991868
[TBL] [Abstract][Full Text] [Related]
18. Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments.
Winstone J; Chadda S; Ralston S; Sajosi P
Orphanet J Rare Dis; 2015 Oct; 10():139. PubMed ID: 26511061
[TBL] [Abstract][Full Text] [Related]
19. [European incentives for orphan medicinal products].
Enzmann H; Lütz J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
[TBL] [Abstract][Full Text] [Related]
20. Cancer drugs for solid tumors approved by the EMA since 2014: an overview of pivotal clinical trials.
Lasala R; Logreco A; Romagnoli A; Santoleri F; Musicco F; Costantini A
Eur J Clin Pharmacol; 2020 Jun; 76(6):843-850. PubMed ID: 32125472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
